KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Invested Capital: 2018-2025

Historic Return on Invested Capital for Halozyme Therapeutics (HALO) over the last 4 years, with Sep 2025 value amounting to 0.31%.

  • Halozyme Therapeutics' Return on Invested Capital rose 10.00% to 0.31% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.31%, marking a year-over-year increase of 10.00%. This contributed to the annual value of 0.25% for FY2024, which is 9.00% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Return on Invested Capital is 0.31%, which was up 6.40% from 0.29% recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Return on Invested Capital peaked at 0.31% during Q3 2025, and registered a low of 0.12% during Q1 2023.
  • Its 3-year average for Return on Invested Capital is 0.20%, with a median of 0.19% in 2024.
  • Data for Halozyme Therapeutics' Return on Invested Capital shows a peak YoY soared of 44bps (in 2021) over the last 5 years.
  • Halozyme Therapeutics' Return on Invested Capital (Quarterly) stood at 0.30% in 2021, then reached 0.13% in 2022, then climbed by 3bps to 0.16% in 2023, then rose by 7bps to 0.23% in 2024, then climbed by 10bps to 0.31% in 2025.
  • Its last three reported values are 0.31% in Q3 2025, 0.29% for Q2 2025, and 0.25% during Q1 2025.